These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 12641491)

  • 1. Prostate cancer: advances in immunotherapy.
    Hurwitz AA; Yanover P; Markowitz M; Allison JP; Kwon ED
    BioDrugs; 2003; 17(2):131-8. PubMed ID: 12641491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for prostate cancer.
    Karnes RJ; Whelan CM; Kwon ED
    Curr Pharm Des; 2006; 12(7):807-17. PubMed ID: 16515497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of potent cytotoxic T lymphocytes against castration-resistant prostate cancer cells by dendritic cells loaded with dying allogeneic prostate cancer cells.
    Hwang EC; Lim MS; Im CM; Kwon DD; Lee HJ; Nguyen-Pham TN; Lee YK; Lee JJ
    Scand J Immunol; 2013 Feb; 77(2):117-24. PubMed ID: 23126536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization.
    Koh YT; Gray A; Higgins SA; Hubby B; Kast WM
    Prostate; 2009 May; 69(6):571-84. PubMed ID: 19143030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer.
    Thompson RH; Allison JP; Kwon ED
    Urol Oncol; 2006; 24(5):442-7. PubMed ID: 16962497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
    Aguilar LK; Guzik BW; Aguilar-Cordova E
    J Cell Biochem; 2011 Aug; 112(8):1969-77. PubMed ID: 21465529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.
    Alberti C
    G Chir; 2017; 37(5):225-235. PubMed ID: 28098061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in prostate cancer immunotherapies.
    Basler M; Groettrup M
    Drugs Aging; 2007; 24(3):197-221. PubMed ID: 17362049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
    Gubin MM; Zhang X; Schuster H; Caron E; Ward JP; Noguchi T; Ivanova Y; Hundal J; Arthur CD; Krebber WJ; Mulder GE; Toebes M; Vesely MD; Lam SS; Korman AJ; Allison JP; Freeman GJ; Sharpe AH; Pearce EL; Schumacher TN; Aebersold R; Rammensee HG; Melief CJ; Mardis ER; Gillanders WE; Artyomov MN; Schreiber RD
    Nature; 2014 Nov; 515(7528):577-81. PubMed ID: 25428507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model.
    Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
    Immunol Lett; 2007 Nov; 113(2):90-8. PubMed ID: 17913245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunotherapy of prostate and bladder cancer.
    Totterman TH; Loskog A; Essand M
    BJU Int; 2005 Oct; 96(5):728-35. PubMed ID: 16144528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in prostate cancer immunotherapy.
    Havranek EG; Whelan MA; Greenhalgh R; Dalgleish AG; Pandha H
    Surg Oncol; 2002 Jun; 11(1-2):35-45. PubMed ID: 12031866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunology and immunotherapy approaches for prostate cancer.
    Elkord E
    Prostate Cancer Prostatic Dis; 2007; 10(3):224-36. PubMed ID: 17420764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of PROSTVAC immunotherapy in prostate cancer.
    Singh P; Pal SK; Alex A; Agarwal N
    Future Oncol; 2015; 11(15):2137-48. PubMed ID: 26235179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer vaccines: current status.
    Hwang LC; Fein S; Levitsky H; Nelson WG
    Semin Oncol; 1999 Apr; 26(2):192-201. PubMed ID: 10597730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The STEAP1(262-270) peptide encapsulated into PLGA microspheres elicits strong cytotoxic T cell immunity in HLA-A*0201 transgenic mice--A new approach to immunotherapy against prostate carcinoma.
    Herrmann VL; Wieland DE; Legler DF; Wittmann V; Groettrup M
    Prostate; 2016 Apr; 76(5):456-68. PubMed ID: 26715028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.